关于召开 2023 年第一次临时股东大会的通知 证券代码：300869 证券简称：康泰医学 公告编号：2023-068 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"）于 2023 年 8 月 8 日召开的公司第四届董事会第三次会议审议通过了《关于召开 2023 年第一 次临时股东大会的议案》，公司董事会决定于 2023 年 8 月 25 日（星期五）召开 2023 年第一次临时股东大会。本次股东大会采用现场投票与网络投票相结合的 方式进行，现就相关事项通知如下： 一、召开会议的基本情况 1. 股东大会届次：2023 年第一次临时股东大会 2. 股东大会的召集人：公司董事会 3. 会议召开的合法、合规性：本次股东大会召开符合有关法律、行政法 规、部门规章、规范性文件和《公司章程》的规定。 4. 会议召开的日期、时间： （1）现场会议日期和时间：2023 年 8 月 25 日（星期五）下午 15：00； （2）网络投票日期和时间： ...

康泰医学系统（秦皇岛）股份有限公司 第四届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"）第四届监事会第 二次会议于 2023 年 8 月 8 日以现场方式在公司二楼会议室召开，公司于 2023 年 7 月 28 日通过电话的方式通知了全体监事。会议应出席监事 3 人，实际出席监事 3 人。本次会议由监事会主席高瑞斌女士召集主持。本次会议的召集、召开及表决程 序符合《公司法》等法律、法规、部门规章、规范性文件和《公司章程》的有关规 定。 二、监事会会议审议情况 经监事会审议和表决，形成决议如下： （一）审议通过《关于医疗设备生产改扩建项目结项并将节余募集资金永久 性补充流动资金的议案》 证券代码：300869 证券简称：康泰医学 公告编号：2023-063 债券代码：123151 债券简称：康医转债 （三）审议通过《关于使用部分暂时闲置募集资金进行现金管理的议案》 经审议，监事会认为：公司在不影响募集资金投资计划正常进行和正常生产经 营的情况下使用可转换公司 ...

中信建投证券股份有限公司 关于康泰医学系统（秦皇岛）股份有限公司使用部分超募资金永 久性补充流动资金的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐人"）作 为康泰医学系统（秦皇岛）股份有限公司（以下简称"康泰医学"或"公司"） 向不特定对象发行可转换公司债券的保荐人，根据《证券发行上市保荐业务管理 办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 13 号——保荐业务》等有关规定，对康泰医学本次使用部分超募资金 永久性补充流动资金的事项进行了核查，并发表如下核查意见： 一、募集资金基本情况 经中国证券监督管理委员会证监许可〔2020〕1563 号文核准，康泰医学于 2020 年 8 月 14 日在深圳证券交易所以每股人民币 10.16 元的发行价格公开发行 41,000,000 股人民币普通股(A 股)，募集资金共计人民币 416,560,000 元，扣除承 销费、推介费及上网发行费共计人民币 25,471,698.11 元后，康泰医学实际收到 上述 A 股的募集资金人民币 391,088,301.89 元，扣除由公司支付的其他发行费用 后，实际募集资 ...

您好，感谢您对公司的关注，公司 2022 年度利润分配预案 已经 2022 年年度股东大会审议通过，根据相关法规和《公司章 程》规定，公司将在年度股东大会召开后两个月内完成分红事宜， 具体实施时间请关注公司后续披露的相关公告，谢谢。 证券代码： 300869 证券简称：康泰医学 康泰医学系统(秦皇岛)股份有限公司投资者关系活动记录 表 编号：202305002 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | 媒体采访 业绩说明会 □ √ | | | 路演活动 □ 新闻发布会 □ | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 30 日 (周二) 下午 14:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事长胡坤 | | 员姓名 | 2、董事、董事会秘书、财务总监郑敏 | | | ...

证券代码：300869 证券简称：康泰医学 公告编号：2023-045 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 关于参加河北辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强于投资者的互动交流，康泰医学系统（秦皇岛）股份有限公司 （以下简称"公司"）将参加由河北证监局、河北省上市公司协会与深圳市全景 网络有限公司联合举办的"2023 年河北辖区上市公司投资者集体接待日活动"， 现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2023 年 5 月 30 日（周二）15:40—17:00。届时公 司高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计 划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢 迎广大投资者踊跃参与！ 特此公告！ 康泰医学系统（秦 ...

证券代码： 300869 证券简称：康泰医学 康泰医学系统(秦皇岛)股份有限公司投资者关系活动记录表 编号：202305001 您好，公司将严格按照相关规则披露定期报告，敬请关注公司公告， 感谢关注。 6、公司有没有人工智能技术储备 | 投资者关系活动类 | 特定对象调研 分析师会议 □ □ | | --- | --- | | 别 | 业绩说明会 □ 媒体采访 √ | | | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及人 | 投资者网上提问 | | 员姓名 | | | 时间 | 2023 年 5 月 18 日 (周四) 下午 15:30~16:30 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网 | | | 络远程的方式召开业绩说明会 | | 上市公司接待人员 | 1、董事长胡坤 | | 姓名 | 2、董事、总经理杨志山 | | | 3、董事、董事会秘书、财务总监郑敏 | | | 4、独立董事李华 | | | 5、保荐代表人孙泉 | | | 投资者提出的问题及公司回复情况 ...

证券代码：300869 证券简称：康泰医学 公告编号：2023-036 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 为充分尊重投资者，提升交流的针对性，现就公司 2022 年度业绩网上说明 会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 05 月 17 日(星期三)15:30 前访问 http://ir.p5w.net/zj/，或扫描下方二维 码，进入问题征集专题页面进行提问。公司将在 2022 年度业绩说明会上，对投资 者普遍关注的问题进行回答。欢迎广大投资者积极参与本次业绩说明会。 特此公告。 康泰医学系统(秦皇岛)股份有限公司董事会 2023 年 5 月 15 日 关于举行 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 康泰医学系统(秦皇岛)股份有限公司（以下简称"公司"）2022 年年度报告 全文及其摘要已于 2023 年 4 月 27 日刊登于创业板信息披露媒体（巨潮资讯网 http://www.cninfo.com.cn）。为使投资者进一步了解公 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥368,699,882.77, representing a 101.21% increase compared to ¥183,239,114.02 in the same period last year[6] - Net profit attributable to shareholders was ¥170,052,052.02, up 131.97% from ¥73,307,986.92 year-on-year[6] - Basic earnings per share rose to ¥0.4232, reflecting a 131.89% increase from ¥0.1825 in the previous year[6] - Operating profit for the quarter was ¥188,205,059.30, up from ¥81,569,879.56, reflecting a growth of 130.5% year-over-year[23] - Net profit attributable to the parent company was ¥170,052,052.02, compared to ¥73,307,986.92 in Q1 2022, marking an increase of 132.5%[23] - The total comprehensive income for the quarter was ¥169,492,486.63, up from ¥72,474,343.11, an increase of 133.4% year-over-year[23] Cash Flow - The net cash flow from operating activities was ¥101,516,355.63, a significant increase of 185.55% compared to ¥35,551,530.90 in Q1 2022[6] - Total cash inflow from operating activities was ¥410,840,410.94, up from ¥220,255,932.02, indicating a growth of about 86% year-over-year[27] - Cash outflow from operating activities increased to ¥309,324,055.31 from ¥184,704,401.12, reflecting a rise of approximately 67%[27] - The net cash flow from investing activities was -¥159,393,812.47, compared to -¥27,462,747.05 in the previous year, showing a significant increase in cash outflow[27] - Cash inflow from financing activities totaled ¥322,376,199.40, while cash outflow was ¥533,152,263.57, resulting in a net cash flow of -¥210,776,064.17 for Q1 2023[28] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,686,584,058.64, a slight decrease of 1.24% from ¥3,732,805,832.45 at the end of the previous year[6] - Total liabilities decreased to ¥1,588,688,602.38 from ¥1,804,472,003.19, representing a decline of about 11.9%[20] - The company's equity attributable to shareholders increased by 8.79% to ¥2,097,895,456.26 from ¥1,928,333,829.26 at the end of the previous year[6] Shareholder Information - The total number of common shareholders at the end of the reporting period is 43,477[12] - The largest shareholder, Hu Kun, holds 46.84% of the shares, totaling 188,189,252 shares[12] - The second-largest shareholder, Wang Guigang, owns 12.72% of the shares, amounting to 51,126,226 shares[12] Expenses - The company reported a significant increase in sales expenses, which rose by 258.01% to ¥34,329,659.15 due to higher platform and technical service fees[10] - The company experienced a 69.12% increase in tax liabilities, amounting to ¥60,207,358.78, driven by higher sales and profit levels[10] - Research and development expenses amounted to ¥25,005,015.83, which is an increase of 28.5% from ¥19,456,247.07 in the previous year[22] - Employee compensation payments rose to ¥59,520,945.56 from ¥42,830,540.37, reflecting an increase of approximately 39% year-over-year[27] Inventory and Receivables - The company reported accounts receivable of approximately ¥161.74 million, slightly up from ¥160.75 million at the beginning of the year[18] - Inventory at the end of the reporting period is approximately ¥514.44 million, an increase from ¥430.24 million at the beginning of the year[18] Cash and Cash Equivalents - The company's cash and cash equivalents at the end of the first quarter are approximately ¥1.13 billion, down from ¥1.39 billion at the beginning of the year[18] - The ending balance of cash and cash equivalents was ¥1,127,658,903.27, down from ¥1,387,323,098.06 at the beginning of the quarter, indicating a decrease of approximately 19%[28] Restricted Shares - The company has a total of 241,722,866 restricted shares, with 16,199,656 shares released during the period[16] - The company plans to unlock certain restricted shares based on executive lock-up conditions[15]

Financial Performance - The company's operating revenue for 2022 was ¥712,114,538.93, a decrease of 21.63% compared to ¥908,712,161.62 in 2021[17] - The net profit attributable to shareholders for 2022 was ¥196,202,558.53, down 44.32% from ¥352,353,389.50 in the previous year[17] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥144,688,613.92, a decline of 57.80% compared to ¥342,894,661.79 in 2021[17] - The basic earnings per share for 2022 were ¥0.49, down 44.32% from ¥0.88 in the previous year[17] - The weighted average return on net assets was 10.54%, a decrease of 10.36% from 20.90% in 2021[17] - The total operating revenue for 2022 was CNY 712.11 million, a decrease of 21.63% compared to CNY 908.71 million in 2021[106] - Revenue from the medical device sector was CNY 708.68 million, accounting for 99.52% of total revenue, also down by 21.68% from CNY 904.84 million in 2021[107] - The blood oxygen product line generated CNY 337.50 million in revenue, representing 47.39% of total revenue, a decline of 26.83% from CNY 461.26 million in 2021[107] - The company reported a significant revenue decline in the Northeast region by 73.15%, while the North China region saw an increase of 128.72%[107] Cash Flow and Investments - The net cash flow from operating activities increased significantly to ¥103,656,852.33, a rise of 2,130.42% from ¥4,647,412.40 in 2021[17] - Total cash inflow from operating activities decreased by 23.00% to ¥796,938,560.84 compared to ¥1,034,963,046.58 in the previous year[146] - Total cash outflow from operating activities decreased by 32.71% to ¥693,281,708.51 compared to ¥1,030,315,634.18 in the previous year[146] - Total cash inflow from financing activities increased by 90.67% to ¥1,744,977,357.32 compared to ¥915,196,350.00 in the previous year[146] - Net cash flow from financing activities increased by 571.77% to ¥781,337,905.36 compared to -¥165,617,705.13 in the previous year[146] - Cash and cash equivalents increased by 467.61% to ¥788,750,705.52 compared to -¥214,564,479.07 in the previous year[146] - The company issued convertible bonds, contributing to a significant increase in cash inflow from financing activities[149] - The total investment amount for the reporting period was CNY 136,134,028.07, representing an increase of 28.05% compared to the previous year's investment of CNY 106,310,458.98[160] Market Position and Industry Trends - The medical device market in China reached approximately ¥958.2 billion in 2022, with a compound annual growth rate of about 17.5% over the past seven years[30] - The company is positioned in a rapidly growing industry, with expectations of a compound annual growth rate of 14.41% over the next five years, potentially exceeding ¥1 trillion by 2025[31] - The global medical device market was valued at approximately $50.43 billion in 2021, with a projected growth to $53.28 billion in 2022[27] - The company operates in a competitive landscape where developed countries hold approximately 79.5% of the global market share, while developing countries like China account for about 19%[28] - The aging population and increasing health demands are expected to drive long-term growth in the medical device industry[64] Research and Development - R&D expenses for the year were 93.25 million yuan, an increase of 41.16% year-on-year, accounting for 13.1% of operating revenue[81] - The company has a stable R&D team of 606 people, accounting for 34.4% of the total workforce, supporting its development strategy and business layout[70] - The company is committed to enhancing its competitive advantage through continuous research and development efforts[35] - The company has developed core technologies for various medical devices, ensuring strong competitiveness and low risk of being replaced by competitors[49] - The company is focusing on expanding its product line with innovative technologies such as non-invasive hemodynamic monitoring and advanced imaging techniques[44] Product Development and Innovation - The company is actively developing new products, including wearable blood oxygen monitors and large self-service health check devices, to meet diverse market needs[37][39] - The company has established a comprehensive product system, mastering core technologies and production processes, with some products achieving industry-leading performance[33] - The company reported a comprehensive range of advanced medical diagnostic equipment, including full-digital B-type ultrasound diagnostic devices and automated biochemical analyzers, enhancing clinical diagnostic capabilities[42] - The company is focusing on expanding its product line, including new medical devices such as a pulse fetal heart rate monitor and a home oxygen machine, which were registered in early 2022[87] - The company plans to enhance its product line and expand its market channels by leveraging its cash flow and operational funds for R&D investments[80] Market Expansion and Sales Strategy - The company has expanded its market presence, selling products in over 150 countries and regions globally, enhancing its brand recognition[33] - The company is actively expanding its global market presence, contributing to the growth of overseas revenue and gaining international recognition[67] - The sales strategy includes a mix of distribution and direct sales, leveraging local distributors' resources to expand into overseas markets[62] - The company is focusing on optimizing production processes and enhancing automation to improve efficiency and product yield[97] - The company is committed to enhancing customer experience through improved service delivery and support for its medical devices[138] Compliance and Regulatory - The implementation of the EU's new medical device regulations (MDR and IVDR) has increased compliance costs and extended certification cycles for domestic manufacturers, but is expected to improve product quality in the long run[32] - The company has established a comprehensive quality management system and has passed ISO9001 and ISO13485 certifications, ensuring high consistency and reliability of its products[75] - The company has received CE certification for several new medical devices, including a fetal monitor and a pulse oximeter, enhancing its product portfolio for international markets[133] - The company has implemented a compliance management strategy for EU regulations, ensuring product compliance for market entry in the EU[103] Risks and Challenges - The company's overseas sales are primarily settled in USD, exposing it to exchange rate risks due to fluctuations in the RMB/USD exchange rate, which could impact pricing competitiveness and operating performance[199] - There is an increasing competition for talent in the medical device industry, particularly for core technology personnel, which could lead to instability in the talent pool if competitive compensation and incentives are not maintained[200] - Failure to retain core technical personnel may result in slowed or halted product development and potential technology leaks, adversely affecting the company's long-term growth[200]

投资者关系活动记录表格式 证券代码：300869 证券简称：康泰医学 康泰医学系统（秦皇岛）股份有限公司 投资者关系活动记录表 编号：202105001 | --- | --- | --- | --- | |----------------|--------------------------------------|--------------------------------------------|-----------------------------------------------------------------| | | | | | | 投资者关系活动 | □特定对象调研 | □分析师会议 | | | 类别 | □媒体采访 | ☑ 业绩说明会 | | | | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | □其他 | （请文字说明其他活动内容） | | | 参与单位名称及 | 参与本次业绩说明会的投资者 | | | | 人员姓名 | | | | | 时间 | 2021 年 5 月 24 日 | 15：30-17：00 | | | 地点 | | 网络形式（全 ...